2020
DOI: 10.1111/dth.14349
View full text
|
Sign up to set email alerts
|
Share

Abstract: Rituximab (RTX) is an anti-CD20 antibody that selectively depletes pre-B and mature B lymphocytes. 1,2 RTX can induce complete remission in 50% to 90% of pemphigus patients. However, relapse occurs from 6 to 26 months. 1,3 Therefore, additional RTX infusions are required but the optimum dose of RTX in relapsing pemphigus patients is still unknown. In this work, 17 pemphigus patients who received RTX and who relapsed were included. None of those patients received any maintenance dose of RTX (Figure 1). All the …

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals